Therapeutics Systems Research Laboratories (United States)

Recent papers from Therapeutics Systems Research Laboratories (United States)

1. In vitro activity of MRS-2541, a novel MetRS inhibitor, against a selection of resistant gram-positive organisms associated with serious hospital infections.2026
2. Making Accessibility Accessible, Part II: Systems, Psychology, and Infrastructure for Lasting Change2026
3. Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastropheScientific Reports · 2025
4. Navigating ortho care amidst war crisis: insights from Al-Aqsa Martyrs’ Hospital’s orthopedic department at Gaza StripFrontiers in Public Health · 2025
5. Li-ion battery safety under aircraft simulated speed impact: Risk and mitigationAerospace traffic and safety. · 2025
6. A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogensAntimicrobial Agents and Chemotherapy · 2024
7. Evaluation of [68Ga]Ga-DOTA-AeK as a Potential Imaging Tool for PET Imaging of Cell Wall Synthesis in Bacterial InfectionsPharmaceuticals · 2024
8. Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo ModelViruses · 2024
9. NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster modelAntimicrobial Agents and Chemotherapy · 2024
10. Evaluation of the Efficacy and Safety of Antiplatelet Therapeutics in RabbitsCurrent Protocols · 2023
11. NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginMolecular Pharmaceutics · 2022
12. The QUICK SCREEN in Action: Project, Product, or Platform Case ExamplesJournal of Commercial Biotechnology · 2022
13. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims DatabaseJournal of Managed Care & Specialty Pharmacy · 2020
14. Biphasic Dissolution as an Exploratory Method during Early Drug Product DevelopmentPharmaceutics · 2020
15. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivoProceedings of the National Academy of Sciences · 2020
16. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivoEndocrine Related Cancer · 2016
17. Cytomegalovirus Protease Targeted Prodrug DevelopmentMolecular Pharmaceutics · 2013
18. Evolution of an Amino Acid Based Prodrug Approach: Stay TunedMolecular Pharmaceutics · 2013
19. Increasing Oral Absorption of Polar Neuraminidase Inhibitors: A Prodrug Transporter Approach Applied to Oseltamivir AnalogueMolecular Pharmaceutics · 2012
20. Expedient Total Synthesis of Triciribine and Its ProdrugsSynthetic Communications · 2011